D&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:25 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001819790-26-000064
Depreciation expense for the three months ended June 30, 2026 and 2025 was $0.8 million and $0.2 million, respectively, and for the six months ended June 30, 2026 and 2025 was $1.0 million and $0.4 million, respectively. The December 31, 2025 leasehold improvements represent construction in progress. In April 2026, in connection with the relocation of the Company’s headquarters, the Company placed its leasehold improvements into service and began recognizing the related depreciation expense. There were no impairments recognized during the three and six months ended June 30, 2026 and 2025.
Item 1. Financial Statements
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s D&A?
- Tarsus Pharmaceuticals, Inc. (TARS) reported D&A of $800K in Q2 2026.
- How has Tarsus Pharmaceuticals, Inc.'s D&A changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s D&A increased by 300.0% year-over-year, from $200K to $800K.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s D&A?
- Over 4 years (2021 to 2025), Tarsus Pharmaceuticals, Inc.'s D&A has grown at a 27.4% compound annual growth rate (CAGR), from $312K to $822K.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
